Lymphocytes circulate in a quiescent (G 0 ) state until they encounter specific antigens. In T cells, quiescence is programed by transcription factors of the forkhead box O (FOXO) and Krü ppel-like factor (KLF) families. However, the transcription factors that regulate B cell quiescence are not known. KLF4 is a candidate tumor suppressor gene in B lymphocytes, and thus a likely candidate for regulating B cell homeostasis. Here, we show that RNA and protein expression of murine KLF4 decreases following B cell activation. Forced expression of KLF4 in proliferating B cell blasts causes a G 1 cell cycle arrest. This effect requires the DNA binding and transactivation domains of KLF4 and correlates with changes in the expression of known KLF target genes. We present evidence that Klf4 is a target gene for FOXO transcription factors, which also suppress B cell proliferation. To determine the effect of KLF4 loss-of-function, we generated mice with B cell-specific deletion of the Klf4 gene. These mice exhibited normal B cell development and function with no evidence of a lowered activation threshold. Collectively, our findings indicate that KLF4 has growth-suppressive properties in B cells but might be redundant with other members of the KLF family in maintaining B cell quiescence.
Introduction
Quiescent cells are non-dividing and exist in a cell cycle phase known as G 0 . Resting lymphocytes are quiescent cells, exhibiting small size, diminished macromolecular synthesis and energy usage and increased stress resistance. It is now clear that cellular quiescence is maintained by an active transcriptional program. Although there has been considerable progress in defining networks of quiescence factors in fibroblasts and T lymphocytes, no transcription factors have been identified as essential for B lymphocyte quiescence. It is important to define such factors since their function is likely essential to oppose auto-antibody production and B lymphoid transformation. Based on gene array comparisons of resting and activated B cells, the forkhead box O (FOXO) and Krüppel-like factor (KLF) families of transcriptional regulators have emerged as candidate quiescence factors in this cell type.
KLFs have growth-suppressive properties in a variety of cell types (1) (2) (3) . KLF4 is of particular interest based on experiments showing dramatically different functions depending on cell context. Over-expression of KLF4 suppresses proliferation in a variety of cell lines, and KLF4 has tumor suppressor properties in colon and gastric cancer. In addition, the KLF4 gene is hypermethylated in adult human T cell leukemia (4, 5) . On the other hand, KLF4 can have oncogenic properties in cells lacking p21 CIP function (6) . KLF4 has also been shown to play contrasting roles in cellular differentiation depending on the context. Whereas the mouse Klf4 gene is required for terminal differentiation of skin epidermis (7), Klf4 is one of four genes sufficient to convert mature fibroblasts into pluripotent stem cells (8) (9) (10) . These interesting findings highlight the importance of investigating KLF4 function in different tissues and cellular responses. We recently identified KLF4 as a candidate tumor suppressor gene in B lymphoid cells (11) ; however, the function and regulation of KLF4 in mature B cells has not been investigated.
In this study, we show that KLF4 is highly expressed in resting B cells and dramatically down-regulated upon activation. Forced expression of KLF4 in proliferating B cells leads to increased cell death and a cell cycle block. The murine Klf4 promoter contains consensus FOXO-binding motifs that bind to FOXO proteins in vitro and are occupied by endogenous FOXO proteins in primary resting B cells. Transfection of FOXO1 augments endogenous Klf4 mRNA to comparable degree as the known target gene, Rbl2/p130 (12) . These data identify Klf4 as a novel FOXO target gene in B cells and provide a functional link between two transcription factors that can oppose proliferation and survival.
Methods

Mice
Animals were studied in accordance with protocols approved by the Institutional Animal Care and Use Committees of University of California-Irvine. Balb/c, El-Bcl-2 transgenic mice (mixed genetic background) and Klf4-flox/CD19-Cre (mixed background) were bred at University of CaliforniaIrvine. The derivation of Klf4-flox mice is described in detail elsewhere (13) . CD19-Cre mice were purchased from The Jackson Laboratory (Bar Harbor, ME, USA) and were bred with Klf4-flox mice to generate mice with selective loss of Klf4 in B cells. Mutant mice were homozygous for the Klf4 floxed allele and heterozygous for Cre and CD19. Control mice were either heterozygous for Cre and wild type for the floxed allele or wild type for Cre and homozygous for the floxed allele.
Primary cells and cell lines
Primary B cells were purified as previously described (14) . Primary B cells and A20 [from American Type Culture Collection (ATCC)] B lymphoma cells were cultured in B cell media (15) . Cos7 cells (obtained from Chris Hughes, University of California-Irvine) and 293T cells (ATCC) were maintained in DMEM with 10% fetal bovine serum and 2 mM glutamine.
Retroviral vectors and transduction
Murine KLF4 and KLF4(DTA) cDNAs were amplified by reverse transcription-PCR and cloned into pBluescript. KLF4(DTA) is an N-terminal deletion of the transcriptional activation domain that is missing the first 109 amino acids. cDNAs for KLF4, KLF4(DTA) and KLF2 were subcloned into the retroviral vectors, pMSCV-IRES-GFP (pMIG) and pMSCV-IRES-hCD4 (pMIC). Myc-tagged KLF4 (gift of Julie Segre, National Institutes of Health) was subcloned into the retroviral vector MSCV-IRES-Thy1.1 (pMIT). KLF4(DDBD), which lacks the DNA-binding domain (amino acids 350-483), and KLF2 cDNA (gift of Kathleen Anderson, University of Cincinnati) were subcloned into pMIC. Myc-tagged versions of KLF4(DTA) and KLF4(DDBD) were generated by PCR cloning from plasmids containing the wild-type KLF4. Retroviral stocks were produced and titered as described (16) . Viruses carrying wild-type KLF4 were consistently lower in titer than those carrying KLF4, presumably due to effects of KLF4 expression on the packaging cell line. Retroviral transduction of LPS-activated splenic B cells was performed as described (15) . Wild-type FOXO1 and wild-type FOXO3a in pMIT were described previously (15) . Myc-dEF1 was excised from pCDNA3 using BamHI and subcloned into the BglII site of pMIT.
Cell cycle, apoptosis and proliferation assays
Retrovirally transduced cells were stained and analyzed by FACS for apoptosis (Annexin V) in hCD4 + populations. Cell cycle analysis was also performed by either sorting cells infected with pMIG vectors for green fluorescence protein (GFP)-positive and -negative populations (Moflo cell sorter, Cytomation) or gating on Thy1.1 + and/or hCD4 + cells and measuring DNA content as described (14) using either propidium iodide (PI) (0.1 mg ml
À1
; Roche, Indianapolis, IN, USA) or 7-aminoactinomycin D (25 lg ml À1 ; Molecular Probes, Eugene, OR, USA) (16) .
Purified B cells were cultured in B cell medium with various mitogens as described (14) . Cells were labeled with carboxyfluoroscein succinimidyl ester (Molecular Probes) as previously described (14) . Cell cycle and protein content analysis, which allowed for the distinction of G 0 versus G 1 , were performed by ethanol fixation of the cells, followed by incubation with RNAse A (0.05 mg ml À1 ), PI (0.05 mg ml À1 ) and 0.1 lg ml À1 FITC (Sigma-Aldrich, St Louis, MO, USA) at 37°C for 30 min. FACS data were analyzed using Flowjo (TreeStar, Ashland, OR, USA).
Electrophoretic mobility shift assay and chromatin immunoprecipitation
Assessment of the binding of FOXO proteins and dEF1 to Klf4 promoter elements in vitro by electrophoretic mobility shift assay (EMSA) and to the endogenous promoter in vivo by chromatin immunoprecipitation (ChIP) were done precisely as described for the Ccng2 and Rbl2 promoters (12) . The sequences of oligonucleotides used for EMSA labeling and competition, and for ChIP PCR of Klf4, are available on request. ChIP analysis of the carbonic anhydrase (CA)-I promoter was done as described (12) except that reactions were stopped after 25 cycles and products detected by Southern blot.
RNA expression analysis (microarray and quantitative PCR)
RNA was prepared from resting and activated splenic B cells and analyzed by microarray (Affymetrix, Santa Clara, CA, USA) as reported (17) . Expression patterns for KLF genes were validated by real-time quantitative PCR (Q-PCR). Briefly, Balb/c B cells at 2.5 3 10 6 ml À1 were either harvested immediately upon purification (T = 0) or treated for 15 min with 10 lM LY294002 (LY), 10 ng ml À1 rapamycin (both from Calbiochem, La Jolla, CA, USA) or vehicle control (0.1% EtOH), followed by stimulation with anti-IgM F(ab#) 2 or cultured in media alone for 12 h. RNA was prepared as previously described (17) . cDNA was synthesized using the iScript cDNA synthesis kit (Bio-Rad, Hercules, CA, USA). Primers for genes of interest (Klf4, Klf2, Klf3 and Rbl2) and housekeeping gene (b-actin) were optimized to amplify products between 75 and 200 nucleotides. Primer sequences are available on request. Q-PCR was performed with SyBr green as previously described (17) . For sorting experiments, A20 cells were transfected as described above and 24 h later stained with anti-Thy1.1-biotin and mixed with magnetically labeled anti-biotin beads (Miltenyi Biotec, Auburn, CA, USA). Positive selection on VarioMacs columns was done according to the manufacturer's instructions. The cells were then cultured in B cell media for another 16 h and harvested for RNA analysis.
Antibodies, immunoblots and immunoprecipitation
Rabbit anti-KLF4 was described previously (18) . Other antibodies were anti-b-actin and anti-cyclin D2 (Sigma-Aldrich), anti-KLF2 (gift of Laurie Glimcher, Harvard School of Public Health), anti-c-Myc (Santa Cruz Biotechnology, Santa Cruz, CA, USA), anti-p21 CIP (BD Biosciences, Mountain View, CA, USA), anti-Erk (Cell Signaling Technologies, Beverly, MA, USA) and anti-Myc (9E10) (Santa Cruz Biotechnology). A total of 2 3 10 6 ml À1 purified Balb/c B cells were either harvested immediately after purification or stimulated for various times at 2 3 10 6 ml À1 with anti-IgM F(ab#) 2 or LPS. Whole-cell lysates were made as described (15) . Samples were resolved on a 7.5% SDS-PAGE gels and immunoblotted as described (14) . For immunoblots examining KLF4 target gene expression, proliferating B cells were transduced with MIG-KLF4 and sorted for GFP-positive and -negative populations as described above, 36 h after infection. Cells (2 3 10 6 ) were lysed in 13 sample buffer for SDS-PAGE and immunoblotting. For detection of genes expressed by retroviral transduction in primary B cells, 2 3 10 6 ml À1 purified Balb/c B cells were harvested 16 h after transduction. Whole-cell lysates were resolved by SDS-PAGE gels and blotted for Myc-tag. In order to detect wild-type Myc-KLF4, cells were first lysed in RIPA lysis buffer, immunoprecipitated with anti-Myc followed by blotting for Myc.
Immunizations and ELISA
Klf4fl/fl+ and WT+ mice were immunized with NP(67)-AECM Ficoll or NP(15)-ovalbumin (OVA) (both from Biosearch Technologies, Novato, CA, USA). Antigens were precipitated with Imject Alum (Pierce) and 100 ll of antigen:alum at a final concentration of 0.5 mg ml À1 (50 lg of antigen) was injected per mouse. Mice were bled at day 0 (before first immunization) and day 7 for NP-Ficoll and NP-OVA-immunized mice. Mice immunized with NP-OVA were additionally bled at day 21 and boosted with same amount of antigen, and then again bled on day 28.
Coating antigen for ELISA was NP(30)-BSA (Biosearch Technologies) at 50 lg ml À1 in 50 ll of total volume. Serum dilutions were also performed in 50 ll volumes. HRP-conjugated rabbit anti-mouse Ig secondary antibodies directed against IgM, IgG1 and IgG2a were used (Zymed, South San Francisco, CA, USA). HRP-conjugated goat anti-mouse Ig secondary antibody directed against IgG3 was used (Southern Biotech, Birmingham, AL, USA).
Results
KLF4 is rapidly down-regulated upon B cell activation
Resting B cells express both KLF4 and KLF2, the family member with greatest homology to KLF4 (17, 19) . Microarray studies from our laboratory and others have shown diminished mRNA expression levels of KLF2 and KLF4 following B cell receptor (BCR) stimulation with anti-IgM (17, 19) . The down-regulation of KLF4 at 2 and 12 h after activation appeared to be more complete than that of KLF2 (Fig. 1A) . In order to validate the microarray data, we checked mRNA expression by real-time Q-PCR in primary B cells. Downregulation of KLF4 12 h after stimulation with anti-IgM was once again much more complete than that of KLF2 when compared with resting (T = 0) cells, although both were statistically significant (Fig. 1B) . A slight down-regulation of KLF3 was also seen (Fig. 1B) , consistent with the array data of Glynne et al. (20) . Western blotting showed that KLF4 is also down-regulated at the protein level following BCR cross-linking and the B cell mitogen LPS (Fig. 1C) . B cells cultured in media alone for 12 h did not down-regulate KLF4 (data not shown). The pattern of regulation for KLF4 in B cells is characteristic of a quiescence factor, expressed in the naive state and down-regulated upon stimulation.
Functional role of KLF4 in B cells
The mRNA and protein expression data showed a correlation between KLF4 down-regulation and the onset of B cell activation. To test whether forced expression of KLF4 could affect ongoing B cell proliferation, we employed a retroviral transduction system for expression in proliferating B cells. We cloned wild-type KLF4 and two KLF4 deletion mutants into pMIG and pMIC. These retroviral vectors allow the bicistronic expression of the gene of interest and the marker proteins GFP or human CD4 (lacking the cytoplasmic tail), respectively. The KLF4DTA mutant lacks sequences encoding the N-terminal transcriptional activation domain (determined by homology with KLF2), and KLF4DDBD lacks the C-terminal DNA-binding domain.
Forced expression of KLF4 in proliferating B cells (LPS blasts) caused an arrest or delay in cell cycle progression, as indicated by a consistently increased percentage of cells in the G 0 /G 1 phase of the cell cycle and a decreased percentage in S phase ( Fig. 2A and B) . Cell size measurements did not suggest arrest in G 0 (data not shown). The cell cycle delay was specific to KLF4 transcriptional activity as neither of the KLF4 deletion mutants (KLF4DTA and KLF4DDBD) had an inhibitory effect on cell cycle progression when compared with cells transduced with vector alone (Fig. 2B ). Myc-tagged KLF4 mutants were readily detected by immunoblot (Fig. 2C, top panel) , indicating that the lack of effect was not simply due to a failure of expression. Effects of KLF2 on B cell proliferation could not be compared with KLF4 as a tagged version of KLF2 appeared to be unstable and was not expressed. Wild-type KLF4 was not detected by direct immunoblotting, likely because viruses carrying this cDNA were always of low titer and transduced a much smaller fraction of cells. Expression of Myc-tagged wild-type KLF4 was validated in primary B cells by initially immunoprecipitating with anti-Myc antibody followed by immunoblotting for the Myc-tag (Fig. 2C) . The effect of KLF4 on B cell proliferation is similar to the phenotype reported previously by our lab for constitutively active FOXO proteins (15) .
Forced expression of KLF4 also led to an increase in cell death in proliferating B cells. The increased cell death was dependent on KLF4 transcriptional activity since KLF4DTA had no effect (Fig. 2D) . Forced expression of KLF4 in B cells from Bcl-2 transgenic mice induced a similar percentage of dying (Annexin V-positive) cells as in non-transgenic B cells (Fig. 2D) . In contrast, the spontaneous apoptosis in cells infected with vector alone or (KLF4DTA) was partially prevented by Bcl-2 expression when compared with littermate control and Balb/c mice, consistent with a spontaneous mitochondrial-mediated death pathway in proliferating B cells.
Considering that the transcriptional and DNA-binding ability of KLF4 were required to suppress B cell proliferation, we evaluated the effects of KLF4 over-expression on candidate target genes. The retroviral transduction system was used to infect B cells with wild-type KLF4. These cells were then sorted, as in Fig. 2A , for GFP-positive and -negative cells. The two populations were then immunoblotted for expression of the proteins c-Myc, cyclin D2 and p21 CIP (Fig. 3) . In other systems, KLF4 or KLF2 suppresses expression of c-Myc and D-type cyclins, and KLF4 augments expression of p21
CIP (4, (21) (22) (23) . KLF4 over-expression in B cells led to an increase in p21 CIP expression and a decrease in c-Myc and cyclin D2 expression. In comparison, we observed that B cell stimulation for 4 h led to an increase in c-Myc and cyclin D2 expression, as would be expected in a proliferating cell such as an activated B cell (24) (25) (26) .
KLF4 mRNA is down-regulated upon B cell activation in a phosphoinositide 3-kinase-dependent manner
The data in Fig. 1 showed that KLF4 mRNA is rapidly downregulated upon B cell stimulation. Upon further investigation, we observed that the phosphoinositide 3-kinase (PI3K) inhibitor LY increased basal expression and prevented antiIgM-induced down-regulation of KLF4 (Fig. 4A) . Since LY inhibits the mammalian target of rapamycin (mTOR) pathway at the same concentration as the PI3K pathway (27, 28), we also pre-treated cells with rapamycin (an inhibitor specific to the mTOR pathway). Cells pre-treated with rapamycin did not show increased KLF4 expression or a reversal in antiIgM-induced down-regulation, demonstrating specificity to the PI3K pathway.
FOXO proteins and dEF1 bind to the Klf4 promoter PI3K-dependent down-regulation of KLF4 represents a pattern consistent with the gene being transcriptionally regulated by the FOXO proteins. FOXO transcriptional function is opposed by phosphorylation mediated by AKT, a kinase activated downstream of PI3K. FOXO proteins have been linked to cellular quiescence in both fibroblasts and T cells (29, 30) . Previously, we showed that FOXO over-expression can suppress B cell proliferation and survival (15) . The effects of FOXO proteins are opposed by the PI3K/AKTsignaling pathway, known to be essential for B cell proliferation and survival (31) . mRNA expression of FOXO target genes Rbl2 and Ccng2 is down-regulated upon BCR engagement in a manner dependent on PI3K (15). Klf4 has not previously been identified as a FOXO target gene. Therefore, we investigated further whether such a transcriptional link exists between FOXO proteins and KLF4, each of which 
We used the MatInspector program (http://www.genomatix. de) and rVISTA (http://genome.lbl.gov/vista/index.html) to search for FOXO consensus binding sites in the Klf4 promoter and found four consensus elements (locations listed in Fig. 4 legend) . These showed a reasonable match to the published core consensus FOXO sequence, TTGTTTAC (32) (33) (34) . We used Cos7 cells transfected with FOXO constructs as a source of cellular extracts for EMSA experiments (12) . Only three of the consensus motifs bound FOXO1 in vitro (Fig. 4B) . FOXO1 binding to all three of these sites appeared to be specific as the band was inhibited or supershifted by pre-incubation with antibodies to FOXO1 but not by an isotype control antibody (Fig. 4B) . Similar results were obtained using extracts of Cos7 cells transfected with FOXO3a (data not shown). EMSA experiments were also done using extracts of primary B cells and consensus site A in the Klf4 promoter. The results showed formation of a specific complex that could be partially supershifted or blocked by anti-FOXO1 or anti-FOXO3a antibodies (Fig. 4C) . Complex formation decreased in anti-IgM-treated B cells relative to resting cells, consistent with inactivation and nuclear export of endogenous FOXO proteins (15) .
We recently reported that another transcription factor, dEF1, binds to the promoters of two known FOXO target genes, Rbl2/p130 and Ccng2/cyclin G2, and synergizes with FOXO to activate these promoters (12) . We found several sites matching the dEF1 consensus sequence AGGTG in the Klf4 promoter. We tested two of these sites, both of which bound in vitro to dEF1 (Fig. 4D) . The binding complex appeared to be also specific as pre-incubation with an antibody against the epitope tag of the myc-dEF1 construct caused a supershift whereas an isotype control did not (Fig.  4D and data not shown) .
To determine if FOXO proteins and dEF1 bind to the Klf4 promoter in resting splenic B cells, we performed ChIP assays. Antibodies specific to FOXO1, FOXO3a and dEF1 each immunoprecipitated fragments of genomic DNA that were amplified by primers specific to the Klf4 promoter region consisting of EMSA probes C and D (Fig. 4B) , whereas a control IgG antibody did not (Fig. 5A) . PCR amplification of the same immunoprecipitates with primers to the promoter of CA-I, which does not contain any consensus FOXO-or dEF1-binding sites, did not reveal any binding (Fig. 5A) . These data show that FOXO proteins and dEF1 are able to bind to their respective consensus binding motifs in the Klf4 promoter in vitro and to the endogenous promoter in primary resting B cells.
FOXO factors up-regulate endogenous KLF4 levels in A20 cells
Next, we assessed whether transfection of FOXO proteins could augment the amount of endogenous KLF4 mRNA in B lymphocytes. We transfected A20 B lymphoma cells with either vector alone (pMIT) or FOXO1 (pMIT-FOXO1) and used magnetic sorting to enrich the population of cells expressing the internal ribosome entry site-linked surface marker Thy1.1. RNA was then isolated from these cells and Q-PCR was performed to determine the expression of KLF4 relative to b-actin. Transfection of FOXO1 led to a 2.8-fold increase of KLF4 mRNA expression when compared with cells transfected with vector alone. As a positive control, we also checked for the expression of Rbl2 (p130) and Ccng2 (cyclin G2), known FOXO target genes in fibroblasts and B cells (12, 30) . p130 and cyclin G2 mRNA were also upregulated in the FOXO1-transfected cells to a similar extent as KLF4 (Fig. 5B) . These data support the conclusion that Klf4 is a FOXO target gene in B cells.
B cell development and function is mostly unaltered in the absence of KLF4
The data above suggested that KLF4 antagonizes proliferation and survival of B cell blasts through its transcriptional activity, yet it did not answer the question of what role KLF4 plays in the development and maintenance of naive B cells. In order to address this, we generated B cell-specific KLF4-deficient mice by crossing Klf4-flox mice (4, 13) with CD19-Cre mice. In CD19-Cre mice, the expression of Cre recombinase is driven by the endogenous CD19 promoter, allowing for the efficient deletion of floxed sequences in early B lineage cells. We verified deletion of Klf4 at the mRNA level by Q-PCR using purified B cells (Fig. 6A) . The results consistently confirmed that ablation of Klf4 in mature B cells was complete and efficient.
Klf4 flox/flox CD19-Cre + mice were compared with littermate controls that were Klf4 flox/flox CD19-Cre À or to Klf4 +/+ CD19-Cre + mice to control for the effects of CD19 heterozygosity or Cre expression. Flow cytometric analysis of developmental and activation markers showed no consistent differences (data not shown). As judged by PI/FITC staining, which measures DNA and protein content, there was no apparent increase in spontaneously activated B cells in the absence of KLF4 (data not shown). Further comparison of KLF4-deficient B cells and their wild-type counterparts showed no significant difference in proliferation when stimulated with various mitogens (Fig. 6B) . Survival of KLF4-deficient B cells in vitro was comparable to wild-type cells, when cultured in either media alone, anti-IgM or IL-4 (data not shown). Additionally, we did not detect any marked differences in antibody production in response to immunization with Tindependent (NP-Ficoll) or T-dependent (NP-OVA) antigens (Fig. 6C) . Collectively, these data suggest that KLF4 is not essential for B cell development or function and raise the possibility that other transcription factors might have compensatory functions in B cell quiescence.
Discussion
Quiescence factors play a vital role in maintaining T cell homeostasis (34, 35) . The study of lymphocyte quiescence CIP and anti-b-actin as a loading control. Band intensities (bar graph) were calculated from scanned autoradiographs using ImageQuant software, and data were normalized to the b-actin signal for that sample.
was propelled by the striking observation that a single transcription factor of the KLF family (KLF2) is both required for maintenance of T cell quiescence and sufficient to drive a leukemic T cell into quiescence (21, 36) . Although a recent study challenged the model that loss of KLF2 leads to spontaneous T cell activation (37) , other work has supported the ) were either unstimulated (Unstim.) or stimulated with various mitogens for 12 h with or without LY or rapamycin (Rap) pre-treatment. Relative expression refers to the ratio of KLF4 RNA to b-actin RNA in the same cells. The data represent the mean 6 SEM of three independent experiments. A t-test was done to determine statistical difference of the relative expression of Klf4 between the anti-IgM-stimulated samples treated with inhibitors. *P < 0.05 (B) FOXO1 mediates a gel shift of three (Klf4-FOXO-A, Klf4-FOXO-C and Klf4-FOXO-D) of the putative consensus binding sites listed below. Whole-cell extracts of Cos7 cells transfected with FOXO1 cDNA (+) or empty vector (À) were used as sources of protein for EMSA analysis. Specificity for three of four binding sites is shown here using the indicated antibodies and competitor oligomers. A representative gel of three independent experiments is shown. Locations of the four FOXO binding consensus sequences in the murine Klf4 regulatory region are as follows: Klf4-FOXO-A, À1822 to À1803; Klf4-FOXO-B, À1206 to À1192; Klf4-FOXO-C, À1103 to À1094 and Klf4-FOXO-D, À170 to À158. (C) Nuclear lysates from primary B cells either unstimulated or stimulated with anti-IgM for 2 h were used for EMSA analysis. Probe Klf4-FOXO-A from panel B was used. The specificity of binding is shown through the use of antibodies and competitor oligos. This experiment was repeated once with similar results. Anti-IgM caused a 40% decrease in band intensity relative to unstimulated cells (average, n = 2). (D) dEF1 binds specifically to two putative sites in the murine Klf4 regulatory region: Klf4-dEF1-A, À1831 to À1827 and Klf4-dEF1-B, À1456 to À1452. Whole-cell extracts of Cos7 cells transfected with dEF1cDNA (+) or empty vector (À) were used as sources of protein for EMSA analysis. A representative of three independent experiments is shown. idea that KLF2 over-expression promotes a quiescent gene expression program (38, 39) . Other examples of transcription factors that program T cell quiescence are the forkhead family members FOXO3a and FOXJ1 (29, 40) . Loss of either of these proteins leads to lymphoproliferation and autoimmunity driven by hyperactive T cells. However, no single transcription factor essential for B cell quiescence has been identified.
Our previous work identified FOXO proteins as candidate quiescence factors that oppose B cell proliferation (15) . In this study, we demonstrate that KLF4, which is closely related to KLF2 and suppresses proliferation in other cell types, also opposes proliferation and survival of activated B cells. These effects of KLF4 on B cell proliferation are reminiscent of FOXO proteins. Furthermore, KLF4 transcription is regulated by FOXO proteins, providing a functional link between two candidate quiescence factors. KLF4 follows the expression pattern expected in a quiescence factor: it is expressed in naive B cells and strongly down-regulated upon stimulation. Similar findings were recently reported in a study of human B cells: KLF4 expression decreases following activation, and forced expression in activated or resting B cells delays cell cycle progression (41) . Interestingly, KLF4 expression in human memory B cells is lower than resting naive cells, which correlates with shorter times to cell cycle entry in memory cells.
Forced expression of KLF4 in B cell blasts not only delays cell cycle progression but also increases cell death. The observation that KLF4 promotes death in proliferating B cells in a manner independent of Bcl-2 expression suggests a distinct mechanism from mitochondrial-induced apoptosis. The effects of KLF4 were dependent on its transcriptional activity and DNA-binding function. The specificity of the effects of KLF4 in primary B cells was further supported by the finding of expression changes of known and potential target genes such as those encoding p21 CIP , cyclin D2 and c-Myc. Further work is necessary to determine whether these or other gene expression changes are required for the ability of KLF4 to induce B cell arrest and death.
Loss of KLF4 did not appear to affect B cell development or proliferation. We did not observe spontaneous B cell expansion or malignancy in mice up to 8 months of age (data not shown). An explanation for the absence of observable phenotype could be that KLF4 family members have redundant functions in B cells. KLF2, KLF3 and KLF4 are expressed in naive B cells and down-regulated upon BCR cross-linking. Therefore, it is feasible that the loss of KLF4 could result in compensation by other members, particularly KLF2. Expression of KLF2 in B cells lacking KLF4 was comparable to the wild-type controls (data not shown). Expression of FOXO transcription factors was also equivalent in wild-type and KLF4-deficient B cells (data not shown). A long-term goal would be to generate mice with combined deletion of KLF4 and other candidate quiescence factors. It is likely that loss of KLF4 could be an initiating event in B cell transformation. These mice can be crossed with mice over-expressing prosurvival proteins in B cells such as Bcl-2 and c-Myc to determine if additional loss of a quiescence factor increases susceptibility to developing leukemias and/ or autoimmunity.
While this paper was under review, Klaewsongkram et al. (42) reported an analysis of KLF4 regulation and function in B cells. Similar to our findings, they showed that KLF4 mRNA decreases following anti-IgM stimulation. They also generated B cell-specific KLF4 knockout mice using the same KLF4-flox and CD19-Cre strains (termed bKLF4À/À in their article) and obtained some different results. They reported small but significant reductions in mature B cells and anti-IgM-mediated proliferation in the bKLF4À/À mice. The reasons for these differing conclusions are not yet clear, but may result from differences in genetic background, vivarium environment or experimental conditions. In any case, both analyses of KLF4-deficient B cells failed to find evidence for a unique role of KLF4 in maintaining B cell quiescence.
Medina et al. ) population. RNA was isolated from these cells and relative expression of cyclin G2, p130 and KLF4 mRNA was determined by Q-PCR analysis as described in Fig. 1A . Relative expression in the pMIT-transfected cells was set to 1 and fold up-regulation of cyclin G2, p130 and KLF4 mRNA expression in the FOXO1-transfected cells is shown. An average of three independent experiments is shown for p130 and KLF4, whereas one experiment was done for cyclin G2 that matched our previously published findings. A t-test was done to determine the statistical difference of fold activation in FOXO1-transfected cells compared with vector alone for p130 and KLF4. *P < 0.05. motifs in the Klf4 promoter were able to bind FOXO proteins in vitro. In addition, both FOXO1 and FOXO3a are bound to the Klf4 promoter in resting B cells in vivo. Supporting the physiological relevance of Klf4 promoter activation by FOXO1, expression of FOXO1 in A20 cells increased endogenous KLF4 mRNA to a similar degree as a known FOXO target gene, Rbl2/p130. In activated KLF4-deficient B cells, FOXO3a over-expression induced comparable cell cycle arrest as in wild-type B cells (data not shown). Although this suggests that KLF4 is dispensable for FOXO function in this in vitro system, it remains possible that KLF4 is an important FOXO target gene in other contexts of B cell function. Fig. 1B recognizes a sequence in exon 3 and is therefore able to verify deletion. Relative expression refers to the ratio of KLF4 RNA to b-actin RNA in the same cells. We were unable to verify loss of protein expression, as supplies of the antiserum used in Fig. 1C had been exhausted and other KLF4 antibodies were not sensitive enough to detect endogenous protein in B cells. (B) A total of 1.5 3 10 5 purified B cells from each genotype were stimulated with the indicated mitogens and harvested 36 h after stimulation. Cells were then fixed and stained for protein content by labeling with FITC and DNA content with PI. The graph shows the percentage of cells in S/G 2 phase of the cell cycle. The data represent the mean 6 SEM of three independent experiments. (C) Mice were immunized with NP-Ficoll and NP-OVA and bled at day 0 and day 7 (top panels). Antibody titer was measured for various Ig isotypes by ELISA, and absorbance (405 nM) was plotted for dilutions in the linear range of detection. For NP-OVA immunizations, mice were boosted at day 21 and bled at day 28 (bottom panel) followed by ELISA to measure antibody titers. Graphs show an average of five independent experiments. Alternatively, KLF4 might be redundant with other FOXO targets genes of the KLF family. Indeed, the Klf2 promoter also contains consensus FOXO-binding sites that bind FOXO1 in EMSA experiments (data not shown). In addition, KLF2 expression is markedly increased by FOXO1 expression in human Jurkat T cells (G. Bismuth, personal communication). Thus, both KLF2 and KLF4 might act downstream of FOXO proteins and contribute to the network of transcription factors in resting B cells.
In conclusion, we have identified Klf4 as a novel FOXO target gene in B cells and shown that KLF4 over-expression causes cell cycle arrest and death in B cell blasts. As reported previously for KLF2 and the established T cell quiescence factors FOXO3a and FOXJ1 (29, 36, 40) , loss of KLF4 alone does not lead to spontaneous B cell activation. These findings indicate that although naive T and B cells are both maintained in G 0 for extended periods, regulation of B cell quiescence differs considerably from that of T cell quiescence. It is worth noting that naive T cells have a much longer life span than naive B cells (years versus months); moreover, activated T cells synthesize autocrine/paracrine growth factors whereas B cells do not. For these reasons, spontaneous T cell activation even at very low frequency might produce more profound effects than spontaneous B cell activation. However, loss of quiescence factors in B cells in conjunction with mutations that promote proliferation or survival might lead to B lymphoid malignancies or autoimmunity.
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